Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Neurology - 7 Nov 2017

Mollenhauer Brit, Caspell-Garcia Chelsea J, Coffey Christopher S, Taylor Peggy, Shaw Leslie M, Trojanowski John Q, Singleton Andy, Frasier Mark, Marek Kenneth, Galasko Douglas

Abstract excerpt

OBJECTIVE: To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them. METHODS: CSF α-synuclein (α-syn), total and phosphorylated tau (t- and p-tau), and β-amyloid 1-42 (Aβ42) were measured at baseline and 6 and 12 months in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine

Share to Longitudinal Studies

Share to Parkinson Disease

Share to Peptide Fragments

Share to tau Proteins

Share to Tomography, Emission-Computed, Single-Photon

Source

Open in PubMed Open full text

Identifiers

PMID: 29030452
DOI: 10.1212/WNL.0000000000004609
PMCID: PMC5679418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.PMID 29030452Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.Semantic proximity Read ↗

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson diseaseSemantic proximity Read ↗

Differences in Blood and Cerebrospinal Fluid Between Parkinson’s Disease and Related DiseasesSemantic proximity Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian DisordersSemantic proximity Read ↗

Cerebrospinal fluid biomarker for Parkinson's disease: An overviewSemantic proximity Read ↗

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Semantic proximity Read ↗

Biomarkers in Huntington's and Parkinson's Disease.Semantic proximity Read ↗

APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.Semantic proximity Read ↗

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.